Page last updated: 2024-11-06

1-benzylimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-Benzylimidazole is an organic compound with the formula C10H10N2. It is a white solid that is soluble in organic solvents. The compound is often used as a precursor to other organic compounds, and it has been shown to have a variety of biological activities. It is also a commonly used reagent in organic synthesis and has been studied for its potential applications in various fields, including pharmaceuticals, pesticides, and materials science.'

1-benzylimidazole: inhibits human thromboxane synthetase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID77918
CHEMBL ID14192
SCHEMBL ID414
MeSH IDM0067512

Synonyms (66)

Synonym
1-benzyl imidazole
IDI1_015267
EN300-43107
HMS3394E11
unii-w4c9z5bcv7
w4c9z5bcv7 ,
nsc126828
n-benzylimidazole
nsc-126828
imidazole, 1-benzyl-
1h-imidazole, 1-(phenylmethyl)-
4238-71-5
1-benzylimidazole
smr000059044
nsc217337
nsc-217337
AE-848/31917030
bdbm7887
1-benzylimidazole (bi)
chembl14192 ,
1-benzyl-1h-imidazole
STK092404
inchi=1/c10h10n2/c1-2-4-10(5-3-1)8-12-7-6-11-9-12/h1-7,9h,8h
2AFX
DB04581
benzylimidazole
1BN ,
1-benzylimidazole, 99%
MLS000069473 ,
MAYBRIDGE3_003880
ccris 5821
NCGC00018145-01
einecs 224-200-4
ai3-52572
HMS2052E11
B3387
AKOS000268328
HMS1442A08
NCGC00018145-02
NCGC00018145-03
MLS001424205
HMS2234L20
CCG-101105
FT-0607409
AM20040449
HMS3371B19
1-benzyl-imidazole
1-benzylimdazole
NC00355
SCHEMBL414
3PB9
J-504251
FS-2656
J-640100
OPERA_ID_1637
mfcd00005296
F1160-0001
DTXSID60195183
AC-8722
CS-0035988
SY013304
1-phenylmethyl-1h-imidazole
cdd 3500
benzylimidazole, 1-
Q27095323
Z57842700

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Some of the more striking expressions of toxicity are the tremors and seizures observed approximately 100 min after exposure of rats to an acutely toxic dose of acrylonitrile (AN)."( Effect of cytochrome P450 inhibitors and anticonvulsants on the acute toxicity of acrylonitrile.
Benz, FW; Nerland, DE, 2005
)
0.33

Dosage Studied

ExcerptRelevanceReference
" The 3-methylcholanthrene-dependent increases in 2- and 3-hydroxylation appear due to induction of a single form of cytochrome P-450, as indicated by similar dose-response relationships and similar changes in sensitivity to the inhibitors."( Biphenyl metabolism by rat liver microsomes: regioselective effects of inducers, inhibitors, and solvents.
Haugen, DA,
)
0.13
" Oral and intravenous dosing with 1-BI, unlike OKY, produced epinephrine reversal in SHR, indicating the blockade of alpha-adrenoceptors."( 1-Benzylimidazole, a thromboxane synthetase inhibitor acutely lowers blood pressure mainly by alpha-adrenoceptor blockade in spontaneously hypertensive rats (SHR).
Cervoni, P; Chan, PS; Lipchuck, LM; Lucas, J; Mateja, N; Ronsberg, MA, 1983
)
1.71
" Platelet accumulation on the injured tissue was further reduced by increasing the dosage to 30 mg/kg."( The reduction of platelet thrombi on damaged vessel wall by a thromboxane synthetase inhibitor in rabbits.
Chen, YC; Hall, ER; Ho, T; Wu, KK, 1982
)
0.26
" When NBI was administered prior to dosing with carb, the increase in DA, decrease in GABA, and biphasic effect on GLu was similar to that seen after dosing with carb only."( S-(N, N-diethylcarbamoyl)glutathione (carbamathione), a disulfiram metabolite and its effect on nucleus accumbens and prefrontal cortex dopamine, GABA, and glutamate: a microdialysis study.
Faiman, MD; Kaul, S; Latif, SA; Lunte, CE; Williams, TD, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (23)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Microtubule-associated protein tauHomo sapiens (human)Potency44.66840.180013.557439.8107AID1468
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency3.54810.794321.275750.1187AID624246
DNA polymerase betaHomo sapiens (human)Potency17.78280.022421.010289.1251AID485314
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Glutaminyl-peptide cyclotransferaseHomo sapiens (human)Ki7.10007.100012.050017.0000AID977610
Chain A, Glutaminyl-peptide cyclotransferaseHomo sapiens (human)Ki7.10007.100012.050017.0000AID977610
Chain X, Glutaminyl-peptide cyclotransferase-like proteinHomo sapiens (human)Ki0.26200.26203.00505.7480AID977610
Chain X, Glutaminyl-peptide cyclotransferase-like proteinHomo sapiens (human)Ki0.26200.26203.00505.7480AID977610
Chain X, Glutaminyl-peptide cyclotransferase-like proteinHomo sapiens (human)Ki0.26200.26203.00505.7480AID977610
Chain A, Glutaminyl-peptide cyclotransferaseHomo sapiens (human)Ki0.26200.26203.00505.7480AID977610
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)0.20000.00011.774010.0000AID625245
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)2.00000.00002.015110.0000AID625249
AromataseHomo sapiens (human)IC50 (µMol)0.15000.00001.290410.0000AID615415
Steroid 17-alpha-hydroxylase/17,20 lyase Rattus norvegicus (Norway rat)IC50 (µMol)77.45670.00161.67077.6700AID269148; AID269149; AID270823; AID270825; AID502080; AID502081
Cytochrome P450 11B1, mitochondrialHomo sapiens (human)IC50 (µMol)0.48220.00050.29022.7800AID459283; AID553065
Translocator proteinRattus norvegicus (Norway rat)IC50 (µMol)154.20000.00010.63934.8100AID270823
Cytochrome P450 11B2, mitochondrialHomo sapiens (human)IC50 (µMol)1.35820.00010.27383.5000AID459282; AID553066
Thromboxane-A synthase Homo sapiens (human)IC50 (µMol)0.60200.00091.230410.0000AID625229
Glutaminyl-peptide cyclotransferaseHomo sapiens (human)Ki2.62300.26202.93587.0000AID1796106; AID1799770
Cytochrome P450 4Z1Homo sapiens (human)IC50 (µMol)6.30005.90006.30006.7000AID1732640; AID1732641
Glutaminyl-peptide cyclotransferaseMus musculus (house mouse)Ki6.40006.40006.40006.4000AID1796111
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Epoxide hydrolase 1Rattus norvegicus (Norway rat)E100230.00006.20006.20006.2000AID208343
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (72)

Processvia Protein(s)Taxonomy
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
C21-steroid hormone biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
glucocorticoid biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
immune responseCytochrome P450 11B1, mitochondrialHomo sapiens (human)
regulation of blood pressureCytochrome P450 11B1, mitochondrialHomo sapiens (human)
sterol metabolic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
aldosterone biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cellular response to hormone stimulusCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cortisol biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cellular response to potassium ionCytochrome P450 11B1, mitochondrialHomo sapiens (human)
glucose homeostasisCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cholesterol metabolic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cortisol metabolic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cellular response to peptide hormone stimulusCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cortisol biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
regulation of blood volume by renal aldosteroneCytochrome P450 11B2, mitochondrialHomo sapiens (human)
renal water homeostasisCytochrome P450 11B2, mitochondrialHomo sapiens (human)
C21-steroid hormone biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
mineralocorticoid biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
sterol metabolic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
aldosterone biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cellular response to hormone stimulusCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cortisol biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cellular response to potassium ionCytochrome P450 11B2, mitochondrialHomo sapiens (human)
potassium ion homeostasisCytochrome P450 11B2, mitochondrialHomo sapiens (human)
sodium ion homeostasisCytochrome P450 11B2, mitochondrialHomo sapiens (human)
glucocorticoid biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cortisol metabolic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cellular response to peptide hormone stimulusCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cholesterol metabolic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
prostaglandin biosynthetic processThromboxane-A synthase Homo sapiens (human)
icosanoid metabolic processThromboxane-A synthase Homo sapiens (human)
cyclooxygenase pathwayThromboxane-A synthase Homo sapiens (human)
intracellular chloride ion homeostasisThromboxane-A synthase Homo sapiens (human)
response to ethanolThromboxane-A synthase Homo sapiens (human)
positive regulation of vasoconstrictionThromboxane-A synthase Homo sapiens (human)
response to fatty acidThromboxane-A synthase Homo sapiens (human)
peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferaseGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
protein modification processGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
arachidonic acid metabolic processCytochrome P450 4Z1Homo sapiens (human)
lauric acid metabolic processCytochrome P450 4Z1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (28)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
steroid 11-beta-monooxygenase activityCytochrome P450 11B1, mitochondrialHomo sapiens (human)
iron ion bindingCytochrome P450 11B1, mitochondrialHomo sapiens (human)
heme bindingCytochrome P450 11B1, mitochondrialHomo sapiens (human)
corticosterone 18-monooxygenase activityCytochrome P450 11B1, mitochondrialHomo sapiens (human)
steroid 11-beta-monooxygenase activityCytochrome P450 11B2, mitochondrialHomo sapiens (human)
iron ion bindingCytochrome P450 11B2, mitochondrialHomo sapiens (human)
steroid hydroxylase activityCytochrome P450 11B2, mitochondrialHomo sapiens (human)
heme bindingCytochrome P450 11B2, mitochondrialHomo sapiens (human)
corticosterone 18-monooxygenase activityCytochrome P450 11B2, mitochondrialHomo sapiens (human)
monooxygenase activityThromboxane-A synthase Homo sapiens (human)
thromboxane-A synthase activityThromboxane-A synthase Homo sapiens (human)
iron ion bindingThromboxane-A synthase Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygenThromboxane-A synthase Homo sapiens (human)
heme bindingThromboxane-A synthase Homo sapiens (human)
12-hydroxyheptadecatrienoic acid synthase activityThromboxane-A synthase Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityThromboxane-A synthase Homo sapiens (human)
protein bindingGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
zinc ion bindingGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
glutaminyl-peptide cyclotransferase activityGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
iron ion bindingCytochrome P450 4Z1Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 4Z1Homo sapiens (human)
heme bindingCytochrome P450 4Z1Homo sapiens (human)
fatty acid in-chain hydroxylase activityCytochrome P450 4Z1Homo sapiens (human)
aromatase activityCytochrome P450 4Z1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
mitochondrionCytochrome P450 11B1, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 11B1, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 11B1, mitochondrialHomo sapiens (human)
mitochondrionCytochrome P450 11B2, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 11B2, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 11B2, mitochondrialHomo sapiens (human)
endoplasmic reticulumThromboxane-A synthase Homo sapiens (human)
endoplasmic reticulum membraneThromboxane-A synthase Homo sapiens (human)
cytosolThromboxane-A synthase Homo sapiens (human)
extracellular regionGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
specific granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
extracellular exosomeGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
tertiary granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
ficolin-1-rich granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 4Z1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (68)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID343680Hexadecane-water distribution coefficient, log D at pH 7.4 by shake-flask technique2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID1184074Solubility of the compound in pH 6.5 phosphate buffer containing 5% DMSO2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID553067Selectivity index, ratio of IC50 for human CYP11B2 to IC50 for human CYP11B12011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.
AID459282Inhibition of human CYP11B2 expressed in chinese hamster V79 cells2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
AID1732640Inhibition of human CYP4Z1 overexpressed in human MCF7 cells using luciferin-3FBE as substrate incubated for 24 hrs followed by substrate addition by luminescence based assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of a novel potent cytochrome P450 CYP4Z1 inhibitor.
AID7817Permeability coefficient (Papp) (Caco-2 cell monolayer)2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
A structure-permeability study of small drug-like molecules.
AID553068Inhibition of human recombinant CYP17 expressed in Escherichia coli at 2 uM using progesterone substrate2011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.
AID54946Inhibition of wild type cytochrome P450cam expressed in Escherichia coli2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Computer-assisted design of selective imidazole inhibitors for cytochrome p450 enzymes.
AID270823Inhibition of rat testis 17-alpha-hydroxylase component of P450-17alpha2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
AID553066Inhibition of human CYP11B2 expressed in hamster V79MZ cells using 11-deoxycorticosterone substrate2011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.
AID269149Inhibition of rat microsomal 17,20-lyase component of P450-17alpha2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
AID270824Inhibition of rat testis 17,20 lyase component of P450-17alpha at 10 uM2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
AID547804Selectivity window, ratio of EC50 for BESM cells to EC50 for Trypanosoma cruzi amastigotes infected in BESM cells2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID18990Partition coefficient (logD7.4) measured using octanol and PBS at pH7.42003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
A structure-permeability study of small drug-like molecules.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID1184069Inhibition of IDO1 (unknown origin) using L-tryptophan substrate incubated for 60 mins in presence of 0.01% Triton-X by HPLC2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID1732641Inhibition of human CYP4Z1 overexpressed in human MCF7 cells using luciferin-BE as substrate incubated for 24 hrs followed by substrate addition by luminescence based assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of a novel potent cytochrome P450 CYP4Z1 inhibitor.
AID459284Selectivity ratio of IC50 for human CYP11B2 to IC50 human CYP11B12010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
AID70215Enhancement of epoxide hydrolase activity1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Structural features of imidazole derivatives that enhance styrene oxide hydrolase activity in rat hepatic microsomes.
AID459283Inhibition of human CYP11B1 expressed in chinese hamster V79 cells2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
AID208356Maximum enhancement of styrene oxide hydrolase activity was reported at compound concentration of 5e-3 M1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Structural features of imidazole derivatives that enhance styrene oxide hydrolase activity in rat hepatic microsomes.
AID270826Inhibition of rat testis 17-alpha-hydroxylase component of P450-17alpha at 10 uM2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
AID615415Inhibition of aromatase using 7-methoxy-4-trifluoromethyl coumarin as substrate after 30 mins by fluorescence-based colorimetric analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and structure-activity relationship of 1- and 2-substituted-1,2,3-triazole letrozole-based analogues as aromatase inhibitors.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID502080Inhibition of 17,20-lyase activity of rat testicular microsomal P450-17alpha2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Synthesis and biochemical evaluation of a range of (4-substituted phenyl)sulfonate derivatives of 4-hydroxybenzyl imidazole-based compounds as potent inhibitors of 17alpha-hydroxylase/17,20-lyase (P45017alpha) derived from rat testicular microsomes.
AID26810Partition coefficient (logP)1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Structural features of imidazole derivatives that enhance styrene oxide hydrolase activity in rat hepatic microsomes.
AID553069Inhibition of human placental microsomes CYP19 at 500 nM using androstenedione substrate2011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.
AID343398Octanol-water distribution coefficient, log D at pH 7.4 by shake-flask technique2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID1732638Inhibition of human CYP4Z1 expressed in permeabilized fission AZ3 yeast cells at 100 nM using luciferin-3FBE as substrate incubated for 3 hrs by luminescence based enzyme bag assay relative to control2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of a novel potent cytochrome P450 CYP4Z1 inhibitor.
AID553065Inhibition of human CYP11B1 expressed in hamster V79MZ cells using 11-deoxycorticosterone substrate2011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.
AID270825Inhibition of rat testis 17,20 lyase component of P450-17alpha2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
AID208343Enhanced styrene oxide hydrolase activity pH 8.71985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Structural features of imidazole derivatives that enhance styrene oxide hydrolase activity in rat hepatic microsomes.
AID547622Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID269148Inhibition of rat microsomal 17-alpha-hydroxylase component of P450-17alpha2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
AID1220389Binding affinity to C-terminal His4-tagged CYP2B4 dH/H226Y mutant (unknown origin) after 2 hrs by isothermal titration calorimetric analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Structure and function of cytochromes P450 2B: from mechanism-based inactivators to X-ray crystal structures and back.
AID1732639Inhibition of human CYP4Z1 overexpressed in human MCF7 cells at 1 uM using luciferin-3FBE as substrate incubated for 24 hrs followed by substrate addition by luminescence based assay relative to control2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of a novel potent cytochrome P450 CYP4Z1 inhibitor.
AID547621Cytotoxicity against BESM cells after 88 hrs by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID502081Inhibition of 17-alpha-hydroxylase activity of rat testicular microsomal P450-17alpha2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Synthesis and biochemical evaluation of a range of (4-substituted phenyl)sulfonate derivatives of 4-hydroxybenzyl imidazole-based compounds as potent inhibitors of 17alpha-hydroxylase/17,20-lyase (P45017alpha) derived from rat testicular microsomes.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1811Experimentally measured binding affinity data derived from PDB2005Proceedings of the National Academy of Sciences of the United States of America, Sep-13, Volume: 102, Issue:37
Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2005Proceedings of the National Academy of Sciences of the United States of America, Sep-13, Volume: 102, Issue:37
Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation.
AID1796106QC Inhibition Testing from Article 10.1021/jm050756e: \\The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship.\\2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship.
AID1799770Inhibitor Assay from Article 10.1074/jbc.M110.208595: \\Structures of human Golgi-resident glutaminyl cyclase and its complexes with inhibitors reveal a large loop movement upon inhibitor binding.\\2011The Journal of biological chemistry, Apr-08, Volume: 286, Issue:14
Structures of human Golgi-resident glutaminyl cyclase and its complexes with inhibitors reveal a large loop movement upon inhibitor binding.
AID1796111QC Inhibition Testing from Article 10.1021/bi051142e: \\Isolation, catalytic properties, and competitive inhibitors of the zinc-dependent murine glutaminyl cyclase.\\2005Biochemistry, Oct-11, Volume: 44, Issue:40
Isolation, catalytic properties, and competitive inhibitors of the zinc-dependent murine glutaminyl cyclase.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2011The Journal of biological chemistry, Apr-08, Volume: 286, Issue:14
Structures of human Golgi-resident glutaminyl cyclase and its complexes with inhibitors reveal a large loop movement upon inhibitor binding.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (89)

TimeframeStudies, This Drug (%)All Drugs %
pre-199023 (25.84)18.7374
1990's14 (15.73)18.2507
2000's24 (26.97)29.6817
2010's24 (26.97)24.3611
2020's4 (4.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.86 (24.57)
Research Supply Index4.53 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index43.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other91 (98.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]